Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons

Annals of Neurology

Volumn 60, Issue 2, 2006, Pages 253-255

  Schapira, Anthony H V ^a,b   Cleeter, Michael W J ^a   Muddle, John R ^a   Workman, Jane M ^a   Cooper, J Mark ^a   King, Rosalind H M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASOME; TYROSINE 3 MONOOXYGENASE; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CELL COUNT; CELL DEATH; CELL LOSS; CONTROLLED STUDY; DENDRITIC CELL; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RAT; STEREOLOGY; SUBSTANTIA NIGRA; WEIGHT GAIN;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CHYMOTRYPSIN; CYSTEINE PROTEINASE INHIBITORS; GROOMING; HAND STRENGTH; MOTOR ACTIVITY; MUSCLE TONUS; MUSCULOSKELETAL EQUILIBRIUM; NEURONS; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, SPRAGUE-DAWLEY; REFLEX; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; WEIGHT GAIN;

EID: 33746823308     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20934     Document Type: Article

References (15)

1. McNaught KS, Perl DP, Brownell AL, et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004;56:149-162.
2. Rogers DC, Peters J, Martin JE, et al. SH1RPA, a protocol for behavioral assessment: validation for longitudinal study of neurological dysfunction in mice. Neurosci Lett 2001;306:89-92.
3. Paxinos G, Watson C. The rat brain in stereotactic coordinates. 4th ed. London: Academic Press, 1998.
4. Janson AM, Moller A. Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodiencephalic hemitransection: an analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience 1993;57:931-941.
5. Pakkenberg B, Moller A, Gundersen HJ, et al. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 1991;54:30-33.
6. Sterio DC. The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 1984;134(pt 2): 127-136.
7. Craiu A, Gaczynska M, Akopian T, et al. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 1997;272:13437-13445.
8. McNaught K, Olanow CW. The proteasome inhibitor-induced model of Parkinson's disease. Ann Neurol 2006;60:243-247.
9. Zeng BY, Bukhatwa S, Hikima A, et al. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann Neurol 2006;60:248-252.
10. Manning-Boǧ AB, Reaney SH, Chou VP, et al. Lack of nigrostriatal pathology in a rat model of proteosome inhibition. Ann Neurol 2006;60:256-260.
11. Bové J, Zhou C, Jackson-Lewis V, et al. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol 2006;60:260-264.
12. Kordower JH, Kanaan NM, Chu Y, et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol 2006;60:264-268.
13. Lang AE, Beal MF. The proteosomal inhibition model of Parkinson's disease: "boon or bust"? Ann Neurol 2006;60:158-161.
14. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003;302:819-822.
15. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8:739-758.